- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01244828
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
February 2, 2022 updated by: Organon and Co
Long-term Study of Asenapine in Subjects With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (Protocol P06238)
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia.
Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple antipsychotic drugs, treatment refractory, or elderly participants with schizophrenia.
The treatment period is up to 52 weeks.
Study Overview
Study Type
Interventional
Enrollment (Actual)
157
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Minimum age of 20 years
Participants who meet at least one of the following:
- current diagnosis of schizophrenia of residual subtype
- received treatment with 3 or more antipsychotic drugs
- treatment-refractory participants with schizophrenia
- 65 years old and over with positive schizophrenia symptoms with score of 3 (mild) or more in 1 or more items in the positive subscale of the Positive and Negative Syndrome Scale (PANSS) at the baseline
- Participants who have a Clinical Global Impressions-Severity (CGI-S) score of at least 4 (moderately ill) at the baseline
Exclusion Criteria:
- Uncontrolled, unstable clinically significant medical condition
- Clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at Screening
- Positive pregnancy test at Screening, or the intention to become pregnant during the course of the study
- Seizure disorder beyond childhood (12 years old or younger)
- History of neuroleptic malignant syndrome
- Allergy or sensitivity to drugs such as psychotropics and antipsychotics
- Known history of or currently treated for narrow angle glaucoma
- Parkinson's disease
- Diagnosis of schizoaffective disorder; schizophreniform disorder
- Concurrent psychiatric disorder other than schizophrenia coded on Axis I; a primary diagnosis other than schizophrenia
- Diagnosis of borderline personality disorder
- Diagnosis of mental retardation or organic brain disorder
- Current (past 6 months) substance abuse or dependence according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria (excluding nicotine)
- Positive drug/alcohol tests at the Screening visit
- Imminent risk of self-harm or harm to others, in the Investigator's opinion
- Substance induced psychotic disorder or a behavioral disturbance thought to be due to substance abuse
- Currently under involuntary inpatient confinement
- Use of a non-approved drug in Japan within 12 weeks prior to informed consent
- Previously treated in an asenapine study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Asenapine
Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
|
5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Extrapyramidal Symptoms
Time Frame: Up to 30 days after last dose of study drug (Up to approximately 56 weeks)
|
This measure reports the overall number of participants with any of a group of adverse events that were defined to represent extrapyramidal symptoms.
The number of participants with each of the individual adverse events within this definition is also presented, for terms that occurred in at least one participant.
For this measure, all adverse event terms within the Medical Dictionary for Regulatory Activities (MedDRA) Standardized MedDRA Query (SMQ) for "extrapyramidal syndrome" were treated as extrapyramidal symptoms.
|
Up to 30 days after last dose of study drug (Up to approximately 56 weeks)
|
Change From Baseline in Weight at Week 52
Time Frame: Baseline and Week 52
|
For each participant, change from baseline in weight was calculated as the Week 52 value minus the baseline value.
|
Baseline and Week 52
|
Change From Baseline in BMI at Week 52
Time Frame: Baseline and Week 52
|
For each participant, change from baseline in BMI was calculated as the Week 52 value minus the baseline value.
|
Baseline and Week 52
|
Change From Baseline in HbA1c at Week 52
Time Frame: Baseline and Week 52
|
Blood samples for determination of HbA1c were obtained at baseline and during the study.
For each participant, change from baseline in HbA1c at Week 52 was calculated as the Week 52 value minus the baseline value.
|
Baseline and Week 52
|
Change From Baseline in Fasting Glucose at Week 52
Time Frame: Baseline and Week 52
|
Blood samples for determination of fasting glucose level were obtained at baseline and during the study.
For each participant, change from baseline in fasting glucose at Week 52 was calculated as the Week 52 level minus the baseline level.
|
Baseline and Week 52
|
Change From Baseline in Insulin at Week 52
Time Frame: Baseline and Week 52
|
Blood samples for determination of insulin level were obtained at baseline and during the study.
For each participant, change from baseline in insulin at Week 52 was calculated as the Week 52 level minus the baseline level.
|
Baseline and Week 52
|
Change From Baseline in Prolactin at Week 52
Time Frame: Baseline and Week 52
|
Blood samples for determination of prolactin level were obtained at baseline and during the study.
For each participant, change from baseline in prolactin at Week 52 was calculated as the Week 52 level minus the baseline level.
|
Baseline and Week 52
|
Change From Baseline in PANSS Total Score at Week 52
Time Frame: Baseline and Week 52
|
The PANSS is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.
It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items).
Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions).
Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal).
For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme.
The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms.
The reported measure is the change from baseline at Week 52 (calculated for a participant as Week 52 value minus baseline value); improvement in symptoms is represented by negative values.
|
Baseline and Week 52
|
Change From Baseline in PANSS Total Score at Final Assessment
Time Frame: Baseline up to Week 52
|
The PANSS is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.
It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items).
Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions).
Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal).
For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme.
The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms.
The reported measure is the change from baseline at the final assessment for a participant (calculated for a participant as final assessment value minus baseline value); improvement in symptoms is represented by negative values.
|
Baseline up to Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 5, 2011
Primary Completion (Actual)
August 21, 2014
Study Completion (Actual)
August 21, 2014
Study Registration Dates
First Submitted
November 18, 2010
First Submitted That Met QC Criteria
November 18, 2010
First Posted (Estimate)
November 19, 2010
Study Record Updates
Last Update Posted (Actual)
February 4, 2022
Last Update Submitted That Met QC Criteria
February 2, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P06238
- 132325 (Registry Identifier: Japic-CTI)
- MK-8274-042 (Other Identifier: Merck protocol number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Asenapine
-
Organon and CoCompleted
-
Lori Davis, MDMerck Sharp & Dohme LLC; Forest LaboratoriesCompletedAn Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress DisorderPosttraumatic Stress DisorderUnited States
-
Organon and CoCompleted
-
Duke UniversityMerck Sharp & Dohme LLCCompleted
-
Organon and CoCompleted
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Completed
-
Organon and CoCompleted